Compare Entegris Inc (ENTG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Entegris Inc trades at $148 (market cap $23.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Entegris Inc is far larger — about 4.7× Travere Therapeutics Inc. Common Stock's market cap, and Entegris Inc pays a 0.26% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ENTG | TVTX | |
|---|---|---|
Market Cap | $23.39B | $5.02B |
Volume | 2,918,074 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $184.00 | $67.52 |
52-Week Low | $68.80 | $26.79 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $26.60B | $5.15B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $161.16, up 0.72% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results anticipated. Revenue remains stable around $3.2 billion, while profitability metrics show improvement, though valuation ratios like a P/E of 80.58 appear elevated. Positive sentiment is driven by AI-related semiconductor demand and recent institutional buying.
The outlook is positive given earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. Upside to the $186.56 consensus price target depends on continued execution and market conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
